GSC-000829

**GSC-000829** is a preclinical, selective fibroblast growth factor receptor 2 and 3 inhibitor being developed by **Changchun Genescience Pharmaceuticals** for FGFR-driven diseases. Publicly available sources describe it as a novel FGFR2/FGFR3-selective inhibitor with improved selectivity over FGFR1 and FGFR4, activity against tumors harboring FGFR2/3 fusions or mutations, and favorable preclinical pharmacokinetic and toxicity characteristics. An AACR 2025 abstract positions the program for **advanced solid tumors with FGFR2/3 aberrations**, while other public drug-database coverage also associates the asset with **achondroplasia**; no approved brand name, INN, dosage form, or route of administration has been publicly established from the sources reviewed.